Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04837651 · ClinicalTrials.gov registry record
Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab
A clinical trial of Multiple Sclerosis and Autoimmune Diseases, sponsored by Dragonfly Research.
- Completed
- Registry status
- 48
- Enrollment target
- 1
- Study location
NCT04837651: Completed study of Multiple Sclerosis and Autoimmune Diseases, sponsored by Dragonfly Research.
NCT04837651 is a study of Multiple Sclerosis and Autoimmune Diseases that has completed, run by Dragonfly Research. The registered enrollment target is 48 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04837651, a study of Multiple Sclerosis and Autoimmune Diseases, has completed, sponsored by Dragonfly Research.
- COMPLETED
- Registry status
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary goal of this study is to provide additional data regarding B and T-cell mediated responses to COVID-19 vaccines in MS patients treated with OCR and to determine which clinical and paraclinical variables correlating with vaccine immunogenicity. B-cell mediated humoral responses and adaptive T-cell mediated cellular responses were measured in patients treated with OCR who received any of the available SARS-CoV-2 vaccines, 3-4 weeks after completion of vaccination.
Primary Outcome
Production of SARS-CoV-2 antibodies in response to the COVID-19 vaccine in patients receiving treatment with ocrelizumab or natalizumab.
Conditions Studied
Interventions
- DEVICE Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test
- DEVICE T-Detect COVID T-cell blood test
Study Locations (1)
Massachusetts
- Dragonfly Research, LLC - Wellesley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2021-03-02 |
| Est. Completion | 2021-07-01 |
What the finished NCT04837651 record still lists
NCT04837651 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (92% lower).
The record links to 8 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test is the first listed.
NCT04837651 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04837651 about?
NCT04837651 is a clinical study titled "Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab". The primary goal of this study is to provide additional data regarding B and T-cell mediated responses to COVID-19 vaccines in MS patients treated with OCR and to determine which clinical and paraclinical variables correlating with vaccine immunogenicity. B-cell mediated humoral responses and adapti...
What is the current status of trial NCT04837651?
This trial is currently completed. The enrollment target is 48 participants. The study started on 2021-03-02. Estimated completion is 2021-07-01.
What conditions does trial NCT04837651 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Autoimmune Diseases, Nervous System Diseases, Immune System Diseases, Pathologic Processes.
What interventions are being tested in trial NCT04837651?
The interventions under investigation include: Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test (DEVICE), T-Detect COVID T-cell blood test (DEVICE).
Who is sponsoring clinical trial NCT04837651?
This trial is sponsored by Dragonfly Research, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04837651 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04837651's enrollment target sits among peer trials
48 187th of 315 higher than 128 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI